News Releases

These are news releases that are related to our company, pipeline and investor efforts. Releases are listed in chronological order and are archived by year. Sign-up to receive news as it is released using the email and RSS tools below.

Oct 6, 2016

Summary Toggle aTyr Pharma Presents Additional Data for Resolaris™ Phase 1b/2 Trial in Adult Patients with Facioscapulohumeral Muscular Dystrophy at the 21st International Annual Congress of the World Muscle Society

SAN DIEGO , Oct. 6, 2016 / PRNewswire / -- aTyr Pharma, Inc. (Nasdaq: LIFE), today announced that additional clinical data from aTyr's Phase 1b/2 Trial (002) in adult patients with FSHD were presented at the 21 st International Congress of the World Muscle Society in Granada, Spain .
Sep 29, 2016

Summary Toggle aTyr Pharma Announces Presentation at the 21st International Annual Congress of the World Muscle Society

SAN DIEGO , Sept. 29, 2016 / PRNewswire / -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of Physiocrine-based therapeutics to address severe, rare diseases, today announced participation in the upcoming 21 st International Annual
Sep 21, 2016

Summary Toggle aTyr Pharma Appoints Industry Veteran in Novel Biology Biologics, David J. King, PhD, as Senior Vice President, Research

SAN DIEGO , Sept. 21, 2016 / PRNewswire / -- aTyr Pharma, Inc. (Nasdaq: LIFE), today announced that David J. King , PhD, has joined the company as Senior Vice President, Research. Dr. King will lead aTyr's research and preclinical efforts to advance its Physiocrine biology and support the clinical
Aug 10, 2016

Summary Toggle aTyr Pharma Announces Second Quarter 2016 Operating Results

- On Track to Announce Data from Three Clinical Trials for Resolaris™ in Rare Genetic Muscle Diseases in 4Q16 - - 2nd Potential First in Class Molecule iMod.Fc, On Track to Enter Clinic in 2017 - - Maintains Strong Cash Position: $96.6 Million at End of 2Q16 - SAN DIEGO , Aug.
Jun 3, 2016

Summary Toggle aTyr Pharma to Present at Jefferies 2016 Healthcare Conference

SAN DIEGO , June 3, 2016 / PRNewswire / -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of Physiocrine-based therapeutics to address severe rare diseases, today announced the Company's participation at the Jefferies 2016 Healthcare Conference
May 11, 2016

Summary Toggle aTyr Pharma Announces First Quarter 2016 Operating Results

Company Continues Development Strategy Leveraging Resokine Pathway SAN DIEGO , May 11, 2016 / PRNewswire / -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of Physiocrine-based therapeutics to address severe rare diseases, today
May 5, 2016

Summary Toggle aTyr Pharma Appoints Grove Matsuoka as Senior Vice President, Product Programs and Planning

SAN DIEGO , May 5, 2016 / PRNewswire / -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of Physiocrine-based therapeutics to address severe rare diseases, today announced that Grove Matsuoka, has joined the company as Senior Vice President,
Apr 29, 2016

Summary Toggle aTyr Pharma to Present at Upcoming May Investor Conferences

SAN DIEGO , April 29, 2016 / PRNewswire / -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of Physiocrine-based therapeutics to address severe rare diseases, today announced the Company's participation in two upcoming investor conferences.
Apr 6, 2016

Summary Toggle aTyr Pharma to Present at 15th Annual Needham & Company Healthcare Conference

SAN DIEGO , April 6, 2016 / PRNewswire / -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of Physiocrine-based therapeutics to address severe rare diseases, today announced the Company's participation at the 15th Annual Needham & Company
Mar 30, 2016

Summary Toggle aTyr Pharma Announces Encouraging Phase 1b/2 Results for Resolaris™ in its First Rare Myopathy Trial

First patient trial of a Physiocrine-based investigational new drug Preliminary analysis shows potential activity signals in three months of treatment Safety, tolerability, immunogenicity & PK profile supports Resolaris program advancement in FSHD and potentially other rare diseases SAN